Tradestie Institutional Equity Comparison Engine · Market Close Nov 17, 2026

SCNI vs PLUR: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

SCNI Wins Head-to-Head Institutional Verdict (4–0 across 6 Pillars · 7–3 Matrix Metrics)

SCNI Overall Winner 6-Pillar Tally: SCNI 4 – 0 PLUR (2 Tie) Matrix Metrics: SCNI 7 – 3 PLUR

As of Nov 17, 2026, Scinai Immunotherapeutics Ltd. (SCNI) is the stronger overall head-to-head candidate over Pluri Inc. (PLUR) in the Tradestie Institutional Equity Comparison Engine, winning 7–3 core matrix metrics and 4–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). SCNI carries a Unified Composite Score of 47.3/100 (HOLD) at $0.38 (N/M Forward P/E, -276.1% operating margin), whereas PLUR carries 28.8/100 (SELL) at $0.94 (3.6x Forward P/E, -2454.5% operating margin).

  • Technical & Structure Timing Caution: SCNI is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 29.0); meanwhile PLUR is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 39.9). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About SCNI vs PLUR
SCNI NASDAQ Head-to-Head Winner
Scinai Immunotherapeutics Ltd. American Depositary Shares
Biological Products, (No Disgnostic Substances)
$0.38
-5.89% 1D
Market Cap $1.1M
TTM Revenue $3.1M
Forward P/E N/M
Beta / 30D Vol 3.85β · 82% Vol
Unified Composite Score
47.3 / 100 HOLD
Tech 43.0 Fund 42.0 Flow 50.0 Mom 60.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -30.2%), weak momentum, RSI 29
RSI-14: 29.0 · SMA20: $0.49 · SMA50: $1.04
PLUR US Equity
Pluri Inc.
Biological Products, (No Diagnostic Substances)
$0.94
-9.19% 1D
Market Cap $15.1M
TTM Revenue $1.0M
Forward P/E 3.6x
Beta / 30D Vol 0.80β · 102% Vol
Unified Composite Score
28.8 / 100 SELL
Tech 15.0 Fund 34.0 Flow 50.0 Mom 40.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -13.4%), weak momentum, RSI 40
RSI-14: 39.9 · SMA20: $1.14 · SMA50: $1.08

6-Pillar Scorecard Institutional Category Breakdown (SCNI 4 – 0 PLUR)

Columns: Metric · SCNI · PLUR
1. Valuation Multiples SCNI
Forward P/E N/M 3.6x
Trailing P/E 0.1x 3.6x
PEG Ratio N/M N/M
EV / Revenue 0.3x 44.6x
2. Growth & Scale SCNI
Revenue Growth (YoY) +572.5% -15.8%
Earnings Growth (YoY) +87.2% +0.0%
TTM Revenue (USD) $3.1M $1.0M
Market Cap $1.1M $15.1M
3. Profitability & Quality SCNI
Gross Margin N/A 44.6%
Operating Margin -276.1% -2454.5%
Net Profit Margin -80.1% 0.0%
Return on Equity (ROE) -26.1% -1022.0%
4. Balance Sheet & Cash Flow SCNI
Cash Generation (TTM) -$6.5M EBITDA -$22M
Cash Flow Margin N/A N/A
Net Cash / Leverage $3.76 Book/Sh · -26.1% ROE $30M Net Debt
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning Tie
Options Structure Phase UNCLASSIFIED UNCLASSIFIED
Current IV / %ile N/A (N/A) N/A (N/A)
Put/Call OI Skew Thin ADR Chain N/A
OBV Trend / Tech Phase NEUTRAL · Markdown NEUTRAL · Markdown
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: SCNI (7) vs PLUR (3)
Institutional Metric SCNI PLUR Criterion Row Edge
Market Capitalization
Scale
$1.1M $15.1M Larger Scale PLUR
Trailing P/E Ratio
Valuation
0.1x 3.6x Lower Multiple SCNI
Forward P/E Ratio
Valuation
N/M 3.6x Lower Multiple PLUR
Revenue Growth (YoY)
Growth
+572.5% -15.8% Higher Growth SCNI
Operating Margin (TTM)
Profitability
-276.1% -2454.5% Higher Margin SCNI
Net Profit Margin
Profitability
-80.1% 0.0% Higher Margin PLUR
Return on Equity (ROE)
Capital Efficiency
-26.1% -1022.0% Higher ROE SCNI
52-Week Range Position
Momentum
5% ($0–$4) 2% ($1–$5) Stronger Trend SCNI
Beta / 30D Volatility
Risk Regime
3.85β · 82% Vol 0.80β · 102% Vol Lower Realized Risk SCNI
Unified Institutional Score
Composite Signal
47.3 / 100 (HOLD) 28.8 / 100 (SELL) Higher Composite SCNI
Trailing 12M Revenue (USD)
Operating Scale
$3.1M $1.0M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A 44.6% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 0.3x EV/Rev N/M PEG · 44.6x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$6.5M EBITDA ($3.76 Book/Sh · -26.1% ROE) -$22M ($30M Net Debt) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon PLUR +60.38 pp
SCNI: -49.29% · PLUR: +11.09%
3M Horizon SCNI +85.14 pp
SCNI: +38.8% · PLUR: -46.34%
6M Horizon SCNI +37.37 pp
SCNI: -25.15% · PLUR: -62.52%
1Y Horizon SCNI +14.4 pp
SCNI: -61.13% · PLUR: -75.53%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on SCNI vs PLUR. Trailing 12-month operating profitability (SCNI -276.1% vs PLUR -2454.5%) and valuation multiples (SCNI N/M vs PLUR 3.6x Forward P/E) are benchmarked directly in Pillar 4 below.

SCNI ADR TTM Benchmark FX-Normalized USD
TTM Revenue$3.1M
Gross MarginN/A
Op. Margin-276.1%
ROE / Fwd P/E-26.1% · N/M
PLUR ADR TTM Benchmark FX-Normalized USD
TTM Revenue$1.0M
Gross Margin44.6%
Op. Margin-2454.5%
ROE / Fwd P/E-1022.0% · 3.6x

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
SCNI UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew Thin ADR Chain
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact SCNI Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
PLUR UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact PLUR Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
SCNI Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $1.1M market capitalization and -276.1% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
PLUR Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $15.1M market capitalization and -2454.5% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ SCNI vs PLUR Key Questions & Quantitative Answers

As of Nov 17, 2026, Scinai Immunotherapeutics Ltd. (SCNI) is the stronger overall head-to-head candidate over Pluri Inc. (PLUR) in the Tradestie Institutional Equity Comparison Engine, winning 7–3 core matrix metrics and 4–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). SCNI carries a Unified Composite Score of 47.3/100 (HOLD) at $0.38 (N/M Forward P/E, -276.1% operating margin), whereas PLUR carries 28.8/100 (SELL) at $0.94 (3.6x Forward P/E, -2454.5% operating margin). Technical & Structure Timing Caution: SCNI is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 29.0); meanwhile PLUR is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 39.9). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

SCNI leads the Growth & Scale pillar: SCNI posts +572.5% YoY revenue growth and +87.2% YoY earnings growth on $3.1M TTM revenue (N/A gross margin, -276.1% operating margin), compared with PLUR at -15.8% YoY revenue growth and +0.0% YoY earnings growth on $1.0M TTM revenue (44.6% gross margin, -2454.5% operating margin). On trailing 12-month operating scale, SCNI generates $3.1M in USD-normalized revenue versus $1.0M for PLUR. In operating R&D and SG&A reinvestment, SCNI deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for PLUR.

SCNI screens cheaper on headline valuation multiples. SCNI trades at N/M Forward P/E, 0.1x Trailing P/E, N/M PEG, and 0.3x EV/Revenue (unreported EBITDA margin), whereas PLUR trades at 3.6x Forward P/E, 3.6x Trailing P/E, N/M PEG, and 44.6x EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against SCNI (-26.1% ROE) versus PLUR (-1022.0% ROE) capital efficiency.

In options market volatility and institutional positioning, SCNI carries N/A implied volatility (N/A, Unclassified), thin ADR options open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (3.85β · 82% Vol realized risk). By comparison, PLUR carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.80β · 102% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 17, 2026. For educational research only; not investment advice.